On 13 October 2026 the FDA recorded a supplement to an abbreviated new drug application for generic buprenorphine (ANDA 207490). Supplements to generic applications usually concern manufacturing, packaging or alignment of the label with the reference product. The record does not describe a new indication, formulation or safety finding.
Nothing changes for perioperative practice, including the continuation of buprenorphine in patients on maintenance treatment, which should follow local guidance.
- No change to buprenorphine indications or dosing follows from this record
- Continue to plan perioperative analgesia for patients on buprenorphine with the prescriber
- Check product-specific details only if a particular generic is involved
Why it matters
Most regulatory entries for established analgesics are housekeeping rather than safety signals.
Don't overread it
A generic licence supplement is not a new indication or safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for anaesthesiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free